Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Las Vegas Endocrinology

Neither a doctor nor a teaching hospital

Research payments

$2,342,428

105 payments

Through program year 2025, Las Vegas Endocrinology is reported as receiving $2,342,428 in research payments, across 105 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,056,796 28
2024 Research $253,995 14
2023 Research $394,154 15
2022 Research $212,695 7
2021 Research $142,733 14
2020 Research $202,216 22
2019 Research $79,839 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. Dexcom, Inc. $1,149,934 74 payments
  2. Eli Lilly and Company $574,849 6 payments
  3. Novartis Pharmaceuticals Corporation $349,162 19 payments
  4. Amgen Inc. $149,883 1 payment
  5. Horizon Therapeutics plc $76,208 1 payment
  6. Globus Medical, Inc. $42,392 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity $327,779 2 payments
  2. Evaluation of Modified Adhesives With Dexcom G7 Sensors (Beta Oh8) $172,417 5 payments
  3. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $159,276 7 payments
  4. A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Teprotumumab in Participants With Moderate-to-Severe Active Thyroid Eye Disease $149,883 1 payment
  5. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $142,819 3 payments
  6. Feasibility Study of the Drug-Releasing Dexcom Continuous Glucose Monitoring (CGM) Sensor (Active Release Oh1 & Oh2) $134,158 4 payments
  7. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $133,663 7 payments
  8. Evaluation of the Performance and Data Delivery Reliability of the Dexcom Continuous Glucose Monitoring (CGM) System $126,947 4 payments
  9. Ysi Feasibility Session Study of the Dexcom Continuous Glucose Monitoring (CGM) System in Adults and Pediatrics With Diabetes Mellitus (G6 He(Ro)) $112,516 3 payments
  10. Feasibility Study of Evaluation of the Performance of the Modified G7 Dexcom Continuous Glucose Monitoring (CGM) System $104,750 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record